Chelsea and Westminster NHS Foundation Trust, London, England.
Department of Emergency Medicine, Newcastle upon Tyne Hospitals NHS Foundation Trust, Teesside University, School of Health & Life Sciences, Middlesbrough, England.
J Ultrasound Med. 2023 Jan;42(1):147-159. doi: 10.1002/jum.15990. Epub 2022 Apr 15.
SARS-CoV-2 can cause respiratory diseases with various manifestations. However, little is known about its potential for lung recovery. Lung ultrasound has shown characteristic changes during COVID-19 and has proven to be useful for triage, diagnosis, and therapy. This study investigated how the recovery process from COVID-19 respiratory disease can be monitored using 12-zone lung ultrasound.
This prospective observational cohort study was conducted in a busy urban emergency department in London, United Kingdom, over a 20-week period between April and October 2020. We followed 24 patients recovering from COVID-19 with varying disease severity using 12-zone lung ultrasound at 2-week intervals and monitored the changes in the prevalence of lung abnormalities previously described in COVID-19 infection (irregular pleura, subpleural consolidation, B-lines, and small localized effusions).
Lung ultrasound showed that the lung recovers significantly over 20 weeks postdisease. Individual lung abnormalities also resolved at different rates. The entire rib space occupied by confluent B-lines wane after the acute phase, whereas irregular pleura and subpleural consolidations resolved more gradually. Separate wide B-lines moving with the pleura during respiration may represent more stable features, indicating residual fibrotic changes. Small, localized effusions appear transiently after the initial acute phase of the disease, peaking at approximately 10 weeks after infection. The measured lung abnormalities were strong predictors of perceived shortness of breath during ambulation.
Lung ultrasound can be a useful tool for long-term monitoring of COVID-19 lung disease, avoiding repeated exposure to ionizing radiation, and may distinguish between acute and past infections.
SARS-CoV-2 可引起表现各异的呼吸道疾病。然而,其肺部恢复潜能知之甚少。肺部超声在 COVID-19 期间显示出特征性变化,并且已被证明在分诊、诊断和治疗方面具有价值。本研究旨在探讨使用 12 区肺部超声如何监测 COVID-19 呼吸道疾病的恢复过程。
这是一项在英国伦敦繁忙的城市急诊室进行的前瞻性观察队列研究,在 2020 年 4 月至 10 月的 20 周内对不同严重程度的 COVID-19 患者进行了研究。我们使用 12 区肺部超声,每 2 周随访一次,监测了 COVID-19 感染中先前描述的肺部异常(不规则胸膜、胸膜下实变、B 线和小局部性胸腔积液)的流行情况。
肺部超声显示,肺部在疾病发生后 20 周内明显恢复。个体肺部异常也以不同的速度消退。整个肋间隙的融合 B 线在急性期后逐渐消失,而不规则胸膜和胸膜下实变则逐渐消退。在呼吸过程中随胸膜移动的单独宽 B 线可能代表更稳定的特征,表明存在残留的纤维化改变。小的、局部性胸腔积液在疾病初始急性期后短暂出现,在感染后约 10 周达到高峰。所测量的肺部异常是行走时呼吸急促的强烈预测指标。
肺部超声可能是 COVID-19 肺部疾病长期监测的有用工具,可避免反复接受电离辐射,并可能区分急性和既往感染。